Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development expenses	$ 53,399	$ 24,903
General and administrative expenses	18,163	17,294
Total operating expenses	71,562	42,197
Interest expense	27	799
Other expense (income)	39	(10,359)
Loss before income tax expense (benefit)	(71,628)	(32,637)
Income tax expense (benefit)	259	(212)
Net loss	$ (71,887)	$ (32,425)
Net loss per share of common stock — basic (in dollars per share)	$ (0.98)	$ (0.62)
Net loss per share of common stock — diluted (in dollars per share)	$ (0.98)	$ (0.62)
Weighted-average shares of common stock outstanding — basic (in shares)	73,211,565	52,181,398
Weighted-average shares of common stock outstanding — diluted (in shares)	73,211,565	52,181,398